Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) achieved 22.5% average weight loss in SURMOUNT-1, the Phase 3 trial that earned its FDA approval
Despite aggressive standard of care prompting surgical resection, radiotherapy and chemotherapy, the five year survival has stagnated at around 7.2% [5,6,7]
Not for Diagnostic or Therapeutic Applications
If you face any issue, feel free to contact us
Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB
US$ 29.59
US$ 29.50
US$ 21.77
US$ 23.11
US$ 20.87
US$ 24.89
US$ 20.79
US$ 25.57
